Breaking News: Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products | Financial Buzz

Breaking News: Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products

Amarantus Bioscience Holdings, Inc. (OTC: AMBS) (“Amarantus,” or AMBS), a biotechnology holding company pursuing proprietary therapeutics and diagnostics through its subsidiaries, today announced that it has completed an exclusive worldwide sublicense agreement for development rights of Cutanogen Corporation’s and MANF Therapeutics, Inc.’s pipelines to Emerald Organic Products (OTC: EMOR, or “Emerald”), a diversified cannabidiol (“CBD”)-focused health sciences company. Emerald now has development rights to Engineered Skin Substitute (ESS), mesencephalic astrocyte-derived neurotrophic factor (MANF) and PhenoGuard for all applications. RHK Capital, a boutique Connecticut-based investment bank, advised Emerald on the transaction.

“This agreement provides Emerald with proprietary, cutting edge regenerative therapeutic candidates and world class biopharmaceutical expertise around which we intend to build a leading life sciences division that will separate Emerald from other emerging CBD health sciences companies,” said Ian Parker, President & CEO of Emerald Organic Products. “We now intend to focus on developing these assets through strategic partnerships to unlock their full potential.”

Under the terms of the executed agreement, Amarantus is receiving an up-front payment of preferred stock in Emerald to be valued at a minimum of $66.6 million (the “Preferred”), and will receive single digit royalties, with a right to buy into up to double-digit royalties until April 2022. The Preferred is convertible into 33,333,333 shares of Emerald common stock in April 2022. Prior to April 2022, Amarantus may convert the Preferred stock to common stock in Emerald upon the common stock trading above $5 on average volume of 1,000,000 shares traded for a period of 20 days. Gerald Commissiong, Amarantus’ President & CEO, is slated to join Emerald’s Board of Directors. Gerald Commissiong, and Elise Brownell, PhD, Amarantus’ EVP of Operations and Project Management, will enter into employment and/or consulting agreements with Emerald under a newly-formed division of Emerald that will be created specific to life sciences. John Commissiong, PhD, Amarantus’ Chief Scientific Officer, will become a scientific adviser for Emerald.

ESS has completed a Phase 1/2 clinical study for the treatment of pediatric severe burns, for which it has received orphan drug designation (ODD) from the US Food & Drug Administration (FDA). MANF has achieved pre-clinical proof of concept in several disease models, including retinitis pigmentosa (RP), retinal artery occlusion (RAO), glaucoma, Parkinson’s disease, diabetes and myocardial infarction, and has received ODD from the FDA for RP and RAO. PhenoGuard is a discovery and target validation platform that led to the discovery of MANF, and which the companies believe could identify therapeutic applications for various cannabinoids. 

Amarantus and Emerald continue to negotiate a transaction for eltoprazine, a product development candidate under development by Elto Pharma, Inc., Amarantus’ joint venture with Psychogenics, Inc.

“We are very pleased to complete the license of ESS, MANF and PhenoGuard to Emerald so that development of these incredibly important assets can move forward, while we continue to work with our partners towards an agreement on eltoprazine,” said Gerald Commissiong, President & CEO of Amarantus. “With this first major milestone now complete, Amarantus is well positioned to continue the recapitalization of its capital structure by initiating its Tier 1 Regulation A offering it filed in September 2019 once it receives clearance by the SEC. We believe that Emerald is positioned to capture significant market share in the CBD space and presents a compelling opportunity for investors to gain exposure to the space. We believe in Emerald’s business plan and intend to work tirelessly to help Emerald become successful.”

About Emerald Organic Growth, Inc.

Emerald Organic Products, Inc. (OTC:EMOR), through its Pura Vida brand, has developed and recently commercialized a line of vitamins and supplements with certain proprietary cannabidiol (CBD) health and wellness products which will be marketed nationally and in certain foreign countries through various marketing and sales distribution channels, including experienced wholesale distributors and a professional e-commerce platform. These hemp-based proprietary Pura Vida CBD products include CBD vitamins, chewable CBD gummies, and gummy bears, drinks, CBD tinctures, CBD cosmetics, and others.

About Amarantus Bioscience Holdings, Inc.

Amarantus Bioscience Holdings (AMBS) is a JLABS alumnus biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. The Company‘s 80.01%-owned subsidiary Breakthrough Diagnostics, Inc., currently a joint venture with Todos Medical, Ltd. has licensed intellectual property rights to the Alzheimer’s blood diagnostic LymPro Test ® from Leipzig University that was originally developed by Dr. Thomas Arendt, as well as certain rights to multiple sclerosis diagnostic MSPrecise™ and Parkinson’s diagnostic NuroPro. Amarantus entered into a joint venture agreement with Todos Medical, Ltd. (OTCQB: TOMDF) to advance the diagnostic assets, and Todos has exercised its exclusive option to acquire Amarantus’ remaining ownership in Breakthrough in exchange for approximately 49% ownership of Todos. The transaction is expected to close in the frist half of 2020. AMBS’ 50.1%-owned subsidiary Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson’s disease levodopa-induced dyskinesia, Alzheimer’s aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquired Cutanogen Corporation from Lonza Group in 2015 and currently owns 90.1% of that subsidiary. Cutanogen is preparing for pivotal studies with Engineered Skin Substitute (ESS) for the treatment of pediatric life-threatening severe burns. ESS is a regenerative medicine-based, autologous full-thickness skin graft technology originally developed by the Shriner’s Hospital that can be used to treat severe burns, as well as several other catastrophic and cosmetic dermatological indications. AMBS’ wholly-owned subsidiary, MANF Therapeutics Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (“MANF”). MANF Therapeutics is developing MANF-based products as treatments for ophthalmological disorders such as Wolfram Syndrome, Retinitis Pigmentosa and Glaucoma, as well as neurodegenerative diseases such as Parkinson’s disease. MANF was discovered by the Company’s Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS’ proprietary discovery engine PhenoGuard, and believes several other neurotrophic factors remain to be discovered. Amarantus also owns approximately 30% of the common shares of Avant Diagnostics, Inc.

Sponsored Content Release. Click for Full Disclosure

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For Amarantus Bioscience Holdings, Inc., financial and corporate news dissemination, has signed a six month agreement with the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. has agreed to eighteen million restricted shares, will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: